- Provides update on the Phase I/IIa trial evaluating lead asset BT1718 in patients with advanced solid tumors - Successfully completed initial public offering (IPO) raising gross proceeds of $64.9 million - Strengthened Board of Directors and clinical leadership team CAMBRIDGE, England , & BOSTON

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Aug. 1, 2019-- Bicycle Therapeutics plc , a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that management will present at the Canaccord Genuity 39 th

Appoints pharmaceutical industry veteran Richard N. Kender , MBA, and life sciences financing professional Janice Bourque , MBA Orderly transition planned for four board members to depart over the next 12 months CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Jul.

Phase I results provide additional clinical activity data for Bicycles CAMBRIDGE, U.K. , & BOSTON --(BUSINESS WIRE)--Jul. 1, 2019-- Bicycle Therapeutics , a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--May 22, 2019-- Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) product platform, today announced the pricing of its initial public offering

CAMBRIDGE, U.K., and BOSTON, Mass., May 9, 2019 –  Bicycle Therapeutics , a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) product platform, today announced two senior appointments to facilitate its expanding and advancing

CAMBRIDGE, U.K., and BOSTON, Mass., May 7, 2019  –  Bicycle Therapeutics , a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) product platform, today announced a collaboration with the Dementia Discovery Fund (DDF) to use  Bicycle 

CAMBRIDGE, U.K., and BOSTON, Mass., April 24, 2019  –  Bicycle Therapeutics , a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) product platform, and Oxurion today announced full enrollment of Oxurion’s Phase I trial designed to

CAMBRIDGE, U.K., and BOSTON, Mass., April 24, 2019  –  Bicycle Therapeutics , a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) product platform, announced today that Punit Upadhyaya, Ph.D., Senior Scientist at Bicycle, will

CAMBRIDGE, U.K., and BOSTON, Mass., April 2, 2019 –  Bicycle Therapeutics , a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) product platform, announced today that Paul Beswick, Ph.D., Bicycle’s Director of UK Chemistry and IP,